Trial reportThe European journal of health economics : HEPAC : health economics in prevention and care2011
Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients.
Trial report in The European journal of health economics : HEPAC : health economics in prevention and care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Cognitive behavioral therapy for anxiety and depression symptoms in people of Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- A systematic review of economic analyses of psychological interventions and therapies in health-related settings.BMC health services research · 2022Pooled it
- Pooled it
- Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies.Journal of cancer survivorship : research and practice · 2013Pooled it
- Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review.The oncologist · 2012Pooled it
- Trial
- Trial
- Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence.BMC cancer · 2013Trial
- The Rise of Health Economics: Transforming the Landscape of Economic Research.Health economics · 2026Article
- Identification of Sub-Groups of Patients Surgically Treated for Melanoma With Affected Health-Related Quality of Life and Psychosocial Well-Being.Journal of surgical oncology · 2025Article
- Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors.PharmacoEconomics · 2021Article
- Cognitive Behavior Therapy for Fear of Cancer Recurrence: A Case Study.Journal of clinical psychology in medical settings · 2018Article
- Worse Urinary, Sexual and Bowel Function Cause Emotional Distress and Vice Versa in Men Treated for Prostate Cancer.The Journal of urology · 2018Article
- Prevalence and correlates of fear of recurrence among adolescent and young adult versus older adult post-treatment cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Article
- Does fear of cancer recurrence predict cancer survivors' health care use?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Article
- A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients.Asia-Pacific journal of oncology nursingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and fear are often associated with chronic conditions such as cancer. This paper targets the cost-effectiveness analysis of a cognitive-behavioral group therapy (CBT) in comparison to a client-centered, supportive-experiential group therapy (SET) in cancer patients with dysfunctional fear of progression. An incremental cost-effectiveness analysis was performed using data from a randomized controlled trial among cancer patients receiving inpatient rehabilitation. The means, 95% confidence intervals [95% CI], incremental cost-effectiveness graphic and acceptability curve were obtained from 1,000 bootstrap replications. A total of 174 patients were included in the economic evaluation. The estimated means [95% CI] of direct costs and reduction of fear of progression were <euro>9,045.03 [6,359.07; 12,091.87] and 1.41 [0.93; 1.92] for patients in the SET and <euro>6,682.78 [4,998.09; 8,440.95] and 1.44 [1.02; 1.09] for patients in the CBT. The incremental cost-effectiveness ratio [95% CI] amounts to minus <euro>78,741.66 [-154,987.20; 110,486.32] for an additional unit of effect. Given the acceptability curve, there is a 92.4% chance that the CBT, compared with the SET, is cost-effective without the need of additional costs to payers. Our main result is the superior cost-effectiveness of the cognitive-behavioral intervention program in comparison to the non-directive encounter group for our sample of cancer patients with high levels of anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.